Brief: Aquestive Therapeutics Receives FDA Acceptance Of New Drug Application (NDA) For Libervant
11/09/2023 13:43
Sept 11 (Reuters) - Aquestive Therapeutics Inc AQST.O :
* AQUESTIVE THERAPEUTICS RECEIVES FDA ACCEPTANCE OF NEW DRUG
APPLICATION (NDA) FOR LIBERVANT (DIAZEPAM) BUCCAL FILM IN
PEDIATRIC PATIENTS AND ASSIGNMENT OF PRESCRIPTION DRUG USER FEE
ACT (PDUFA) DATE
* PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET GOAL DATE
SET FOR
APRIL 28, 2024
Source text for Eikon: ID:nGNXc3K4x8
Further company coverage: AQST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million